NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer. — PMID 29802158

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

Linked entities

Linked entities (4)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 4

cancerPancreatic Adenocarcinomacivic_curation1.00
drugAfatinibcivic_curation1.00
geneNRG1civic_curation1.00
variantNRG1 Fusioncivic_curation1.00

Curated evidence

Evidence citing this paper (2)

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
NRG1 Fusion2
Afatinib	Pancreatic Adenocarcinoma	Predictive	C	Supports Sensitivity Response	4	accepted	EID6273 In patients with KRAS wild-type (KRASwt) tumors druggable gene fusions have been identified. These alterations included recurrent NRG1 rearrangements predicted to drive PDAC development through aberra… (full text at CIViC) PMID 29802158 · Heining et al., 2018 · Open in CIViC	civic
Erlotinib + PertuzumabCombination	Pancreatic Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	submitted	EID7534 In patients with KRAS wild-type (KRASwt) tumors druggable gene fusions have been identified. These alterations included recurrent NRG1 rearrangements predicted to drive PDAC development through aberra… (full text at CIViC) PMID 29802158 · Heining et al., 2018 · Open in CIViC	civic